



ImpediMed Limited
1/50 Parker Court
Pinkenba, QLD, 4008
Australia

E: investorrelations@impedimed.com
W : impedimed.com

26 February 2026

Companies Announcements Office
Australian Securities Exchange

Appendix 4D and Interim Financial Report

In accordance with ASX Listing Rule 4.2A, ImpediMed Limited (ASX:IPD) provides the attached Appendix 4D and Interim Financial Report for the half-year ended 31 December 2025.

Approved for release by the Board of ImpediMed Limited.

For more information, contact Leanne Ralph, Company Secretary, at leanne.ralph@bellev.com.au

For personal use only

ImpediMed Limited

ABN 65 089 705 144

Appendix 4D

for the half-year ended 31 December 2025
(previous corresponding period: half-year ended 31 December 2024)

The information contained in this document should be read in conjunction with the financial statements for the year ended 30 June 2025 and any public announcements made by ImpediMed Limited and its controlled entities (the "Group") during the interim reporting period in accordance with continuous disclosure obligations arising under the Corporations Act 2001.

Results for announcement to the market

	Current period	Increase / Decrease	Movement %
	\$000		
2.1 Revenue from ordinary activities	7,516	Increase	25%
2.2 Loss from ordinary activities after tax attributable to members	-12,282	Decrease	10%
2.3 Net loss for the period attributable to members	-12,349	Decrease	25%
2.4 Dividends	NIL		
There were no dividends declared and paid during the half year on ordinary shares. There were no dividends proposed and not yet recognised as a liability during the half year.			
2.5 Dividend Record Date	Not applicable		
2.6 Explanation of operating performance			
Refer to the Directors' Report.			

Net tangible assets per ordinary security

	Current period	Previous corresponding period
	\$	\$
Net tangible assets (\$000)	9,023	32,316
Issued share capital at reporting date (\$000)	336,147	336,147
Number of shares on issue at reporting date	2,038,299,523	2,024,283,759
Net tangible assets per ordinary security	0.004	0.02

Acquisitions and divestments

N/A

Details of dividends

There were no dividends paid or payable during the period ended 31 December 2025.

Dividend Reinvestment Plans

The Group has no dividend reinvestment plan.

Associates and joint ventures

There are no equity accounted associates and joint venture entities.

Accounting standards

The Half-Year Financial Report for the group has been prepared in accordance with Australian Equivalents to International Financial Reporting Standards.

Auditors' review report

The review report prepared by the independent auditor Ernst & Young is not subject to any dispute or qualification, and is provided with the Half-Year Financial Report.

For personal use only

For personal use only

impedimed[®]

HALF-YEAR REPORT

31 December 2025

The information in this report should be read in conjunction with the 30 June 2025 Annual Report.

Directors' report

For the half-year ended 31 December 2025

The Directors submit their report together with the interim consolidated financial report for ImpediMed Limited (the Company) and its subsidiaries (together the Group) for the half-year ended 31 December 2025, and the Auditor's review report thereon.

Principal activities

ImpediMed Limited is a medical technology company with a device that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

The principal activities of the Group during the period were the development, manufacture and sale of BIS systems and software services with a focus on the early detection of lymphoedema.

The Company produces a family of FDA-cleared and CE Marked medical systems, including SOZO® for multiple indications including lymphoedema, heart failure and body composition. ImpediMed's systems are sold in select markets globally.

Directors

During the period and to the date of this report, the Board of ImpediMed Limited comprised Christine Emmanuel Donnelly (Chair), Janelle Delaney, Andrew Grant, Fiona Bones, Erik Anderson, Parmjot Bains (Managing Director and CEO) and McGregor Grant (Chief Financial & Operating Officer and Executive Director).

Review of results and operations

Total revenue for the half-year ended 31 December 2025 was \$7.5 million, up \$1.5 million or 25% compared with \$6.0 million in the prior corresponding period. The increase in revenue was primarily attributed to an increase in SOZO Usage Fees, which was \$7.2 million in the current period compared with \$5.7 million in the prior corresponding period.

Cost of goods sold for the current period were \$0.9 million compared with \$0.7 million in the prior corresponding period. Gross margin, as a percentage of revenue, was 87% compared with 88% in the prior corresponding period.

Total operating expenses for the half-year ended 31 December 2025 were \$18.1 million, compared with \$17.3 million in the prior corresponding period.

Other income for the half-year ended 31 December 2025 was \$0.7 million compared with \$0.5 million in the prior corresponding period. The other income relates to research and development tax credits which the Group accrues for when there is reasonable assurance of receipt. Further details are set out in note 6 of the interim consolidated financial report.

Cash and cash equivalents were \$18.8 million at 31 December 2025 compared with \$22.2 million at 30 June 2025.

Net cash flows used in operating activities for the period ended 31 December 2025 were \$8.5 million compared with \$7.8 million in the prior corresponding period. In the current period, interest received of \$0.5 million (compared to \$0.5 million in the prior corresponding period) has been reclassified from operating to investing activities to better reflect the nature of the cash flows.

Net cash flows from financing activities for the period ended 31 December 2025 were \$6.1 million compared with \$0.2 million used in the prior corresponding period. The increase in net cash flows was primarily from the additional drawdown of US\$5.0 million under the capital growth facility with SWK Funding LLC (Tranche 2), following the achievement of prescribed FY25 sales target.

Subsequent events

There were no subsequent events occurring after the balance sheet date that would have a material impact on the financial report for the period ended 31 December 2025, other than those disclosed in Note 16.

Directors' report

For the half-year ended 31 December 2025

Rounding

The amounts contained in this report and in the interim consolidated financial statements have been rounded to the nearest \$1,000 (where rounding is applicable) and where noted (\$'000) under the option available to the Company under ASIC Instrument 2016/191. The Company is an entity to which that instrument applies.

Auditor's Independence Declaration and Non-Audit Services

A copy of the Auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 4.

This report is made and signed in accordance with a resolution of the Directors pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the Directors



Fiona Bones
Director

26 February 2026

Auditors' independence declaration

For the half-year ended 31 December 2025



**Shape the future
with confidence**

Ernst & Young
111 Eagle Street
Brisbane QLD 4000 Australia
GPO Box 7878 Brisbane QLD 4001

Tel: +61 7 3011 3333
Fax: +61 7 3011 3100
ey.com/au

Auditor's Independence Declaration to the Directors of ImpediMed Limited

As lead auditor for the review of the half-year financial report of ImpediMed Limited for the half-year ended 31 December 2025, I declare to the best of my knowledge and belief, there have been:

- a. No contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review;
- b. No contraventions of any applicable code of professional conduct in relation to the review; and
- c. No non-audit services provided that contravene any applicable code of professional conduct in relation to the review.

This declaration is in respect of ImpediMed Limited and the entities it controlled during the financial period.

A handwritten signature in black ink that reads 'Ernst & Young'. Below the signature is a horizontal line with two dots at its ends, resembling a stylized underline or a signature flourish.

Ernst & Young

A handwritten signature in black ink that reads 'm Madhu'. Below the signature is a horizontal line with two dots at its ends, similar to the one above.

Madhu Nair
Partner
26 February 2026

A member firm of Ernst & Young Global Limited
Liability limited by a scheme approved under Professional Standards Legislation

For personal use only

Directors' declaration

For the half-year ended 31 December 2025

Directors' declaration

In the opinion of the Directors:

- (a) The interim financial statements and notes of the consolidated entity for the half-year ended 31 December 2025 are in accordance with the Corporations Act 2001, including:
 - (i) giving a true and fair view of the consolidated entity's financial position as at 31 December 2025 and of its performance of the half-year ended on that date; and
 - (ii) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the Corporations Regulations 2001.
- (b) There are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

On behalf of the Board



Fiona Bones
Director

26 February 2026

Consolidated statement of profit and loss and other comprehensive income

For the half-year ended 31 December 2025

	Notes	Half-year ended 31 Dec 2025 \$000	Half-year ended 31 Dec 2024 \$000
Revenue from contracts with customers	5	7,516	6,008
Cost of goods sold		(940)	(717)
Gross profit		6,576	5,291
Other income	6	684	466
Salaries and benefits	7	(10,332)	(9,460)
Share-based payments	12	(651)	(1,418)
Clinical trials		(73)	(62)
Administration		(1,576)	(1,566)
Depreciation and amortisation		(2,109)	(2,207)
Consultants and professional fees		(1,451)	(956)
Other expenses		(1,932)	(1,665)
Results from operating activities		(10,864)	(11,577)
Finance income	6	468	442
Finance expense	6	(1,872)	-
Net finance (expense)/ income		(1,404)	442
Loss from operations before income tax		(12,268)	(11,135)
Income tax		(14)	(11)
Loss from operations after income tax expense attributable to owners of the parent entity		(12,282)	(11,146)
Other comprehensive loss/(gain)			
Items that may be reclassified subsequently to profit or loss:			
Exchange difference on foreign currency translation		(67)	1,301
Other comprehensive (loss)/gain for the period, net of tax		(67)	1,301
Total comprehensive loss for the year attributable to owners of the parent entity		(12,349)	(9,845)
		Cents	Cents
Basic and diluted loss per share	3	(0.6)	(0.6)

The consolidated financial statements should be read in conjunction with the accompanying notes.

Consolidated statement of financial position

As at 31 December 2025

	Notes	31 Dec 2025 \$000	30 Jun 2025 \$000
Assets			
Current assets			
Cash and cash equivalents	8	18,847	22,183
Trade and other receivables	9	2,891	2,964
Contract assets		865	689
Inventories		2,270	861
Prepayments and other current assets		798	813
Total current assets		25,671	27,510
Non-current assets			
Other financial assets		73	73
Contract assets		229	227
Property, plant and equipment		174	223
Right of use assets		664	660
Intangible assets	10	11,552	12,967
Total non-current assets		12,692	14,150
Total assets		38,363	41,660
Liabilities			
Current liabilities			
Trade and other payables		2,434	1,550
Contract liabilities		2,446	2,328
Employee benefits liabilities		1,252	1,227
Provisions		25	15
Lease liabilities		303	266
Interest payable	13	397	276
Total current liabilities		6,857	5,662
Non-current liabilities			
Contract liabilities		1,116	1,167
Employee benefits liabilities		44	36
Provisions		73	74
Lease liabilities		381	433
Borrowings	13	20,869	13,792
Total non-current liabilities		22,483	15,502
Total liabilities		29,340	21,164
Net assets		9,023	20,496
Equity			
Issued capital	11	336,147	336,147
Reserves		39,347	38,538
Accumulated losses		(366,471)	(354,189)
Total equity		9,023	20,496

The consolidated financial statements should be read in conjunction with the accompanying notes.

Consolidated statement of changes in equity

For the half-year ended 31 December 2025

	Notes	Reserves						Accumulated Losses \$000	Total \$000
		Issued Capital \$000	Share based payments \$000	Equity escrow \$000	Foreign currency \$000	Warrants reserve	Total reserves \$000		
At 1 July 2024		336,147	23,530	3,698	8,230	-	35,548	(330,952)	40,743
Loss for the period from continuing operations		-	-	-	-	-	-	(11,146)	(11,146)
Other comprehensive gain		-	-	-	1,301	-	1,301	-	1,301
Total comprehensive gain/(loss) for the period		-	-	-	1,301	-	1,301	(11,146)	(9,845)
Equity transactions:									
Share-based payments	12	-	1,251	167	-	-	1,418	-	1,418
At 31 December 2024		336,147	24,781	3,865	9,621	-	38,267	(342,098)	32,316
At 1 July 2025		336,147	24,998	3,834	9,232	474	38,538	(354,189)	20,496
Loss for the period		-	-	-	-	-	-	(12,282)	(12,282)
Other comprehensive loss		-	-	-	(67)	-	(67)	-	(67)
Total comprehensive loss for the period		-	-	-	(67)	-	(67)	(12,282)	(12,349)
Equity transactions:									
Share-based payments	12	-	427	224	-	-	651	-	651
Issue of ordinary warrants		-	-	-	-	225	225	-	225
At 31 December 2025		336,147	25,425	4,058	9,165	699	39,347	(366,471)	9,023

The consolidated financial statements should be read in conjunction with the accompanying notes.

Consolidated statement of cash flows

For the half-year ended 31 December 2025

	Notes	Half-year ended 31 Dec 2025 \$000	Half-year ended 31 Dec 2024 \$000
Cash flows from operating activities			
Receipts from customers (inclusive of GST and sales tax)		7,228	6,137
Payments to suppliers (inclusive of GST and sales tax)		(6,732)	(5,123)
Payments to employees		(10,239)	(9,700)
Government tax incentives and other receipts		1,230	915
Net cash flows used in operating activities		(8,513)	(7,771)
Cash flows from investing activities			
Development expenditures and purchase of intangibles		(475)	(591)
Interest received		462	496
Net cash flows used in investing activities		(13)	(95)
Cash flows from financing activities			
Proceeds from borrowings	13	7,676	-
Interest paid		(1,451)	-
Payment of lease liabilities		(173)	(222)
Net cash flows from/(used) in financing activities		6,052	(222)
Net decrease in cash and cash equivalents		(2,474)	(8,088)
Net foreign exchange differences		(862)	1,149
Cash and cash equivalents at the beginning of the period		22,183	24,632
Cash and cash equivalents at the end of the period	8	18,847	17,693

The consolidated financial statements should be read in conjunction with the accompanying notes.

Notes to the consolidated financial statements

For the half-year ended 31 December 2025

1. Basis of preparation

ImpediMed Limited (the Company) is a listed public company limited by shares and incorporated in Australia. The interim consolidated financial statements of the Company as at and for the half-year ended 31 December 2025 comprises ImpediMed Limited and its subsidiaries (the Group). The interim consolidated financial statements are presented in Australian dollars.

The interim consolidated financial statements for the half-year ended 31 December 2025 have been prepared in accordance with AASB 134 *Interim Financial Reporting* and the Corporations Act 2001.

The interim consolidated financial report does not include all the information normally included within the Annual financial report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and cashflow activities of the consolidated entity as the Annual financial report.

The interim consolidated financial report should be read in conjunction with the Annual financial report for the year ended 30 June 2025 and considered together with any public announcements made by the Group during the half-year ended 31 December 2025 in accordance with the continuous disclosure obligations of the ASX listing rules.

The accounting policies and methods of computation are the same as those adopted in the most recent Annual financial report.

Comparatives

Interest received has been reclassified from operating activities to investing activities to better reflect the nature of the cash flows and the Group's cash management practices. The comparative information has been restated accordingly.

Going concern

These interim consolidated financial statements have been prepared on a going concern basis, which assumes continuity of normal business activities, the realisation of assets and the settlement of liabilities in the ordinary course of business. The Group had cash of \$18.8 million (30 June 2025: \$22.2 million), and long-term borrowings of \$20.9 million (30 June 2025: \$13.8 million). The Group incurred a net loss of \$12.3 million for the half-year ended 31 December 2025 (half-year ended 31 December 2024: net loss of \$11.1 million) and had net cash outflows from operating activities of \$8.5 million (half-year ended 31 December 2025: net cash outflows of \$7.8 million). In July 2025, following the achievement of prescribed FY25 sales target, the Group drew an additional US\$5.0 million under the capital growth facility with SWK Funding LLC ('Tranche 2'), and the interest-only period was extended by 12 months to February 2028.

The Directors, in their consideration of the appropriateness of the going concern basis for the preparation of the interim consolidated financial statements, have prepared a cash flow forecast for the 12 months from the date of signing these financial statements. The cashflow forecast demonstrates the Group will continue to generate operating losses and net cash outflows from operations. In addition to managing costs and increasing cash inflows from customers, the Group's future viability is dependent upon raising additional capital and maintaining access to its existing borrowing facilities.

Should the Group be unable to manage cash flows at amounts as necessary to meet future operating plans, a material uncertainty would exist that may cast significant doubt on the ability of the Group to continue as a going concern, and therefore, whether it will realise its assets and extinguish its liabilities in the ordinary course of business.

The Directors are confident the Group will be able manage cashflows and continue to be able to pay its debts as and when they fall due for a period in excess of 12 months from the date the half-year report has been signed and thus continue as a going concern. On this basis, it is appropriate to prepare the financial statements on the going concern basis. No adjustment has been made in the interim consolidated financial statements relating to the recoverability and classification of recorded asset amounts and to the classification of liabilities that might be necessary should the Group be unable to continue as a going concern.

Notes to the consolidated financial statements

For the half-year ended 31 December 2025

2. Revenue from contracts with customers

Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods or services. The Group accounts for its revenue in accordance with AASB 15 *Revenue from Contracts with Customers*.

3. Earnings per share (EPS)

Basic EPS is calculated as net loss attributable to members of the parent entity, adjusted to exclude any costs of servicing equity (other than dividends) and preference share dividends, divided by the weighted average number of ordinary shares, adjusted for any bonus element.

Diluted EPS is calculated as the net loss attributable to ordinary equity holders divided by the sum of the weighted average number of ordinary shares and the weighted average number of convertible instruments. For the half-year ended 31 December 2025, diluted EPS is equal to basic EPS as the Group is currently in a loss position and any conversion of instruments to ordinary shares would have an antidilutive effect on earnings per share.

As at 31 December 2025, there were 64,687,113 (31 December 2024: 62,390,476) options and 15,865,377 (31 December 2024: 30,426,569) performance rights on issue.

	Half-year ended 31 Dec 2025 \$000	Half-year ended 31 Dec 2024 \$000
Net loss attributable to ordinary equity holders of the parent used in calculating earnings per share	(12,282)	(11,146)
	Number	Number
Weighted average number of ordinary shares used in calculating earnings per share	2,034,058,119	2,023,322,997
	Cents	Cents
Basic and diluted loss per share	(0.6)	(0.6)

4. Dividends

There were no dividends paid or proposed during the current period and to the date of this report (2025: Nil).

5. Segment reporting

Operating segment

An operating segment is a component of an entity that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same entity), whose operating results are regularly reviewed by the entity's chief operating decision maker, the Chief Executive Officer, to make decisions about resources to be allocated to the segment and assess its performance and for which discrete financial information is available.

For the half-year ended 31 December 2025, consistent with the prior year, the Group identified the Medical segment as the sole operating segment. During the period, the Chief Executive Officer reviewed the business revenue information within the Medical segment, consisting of the Group's SOZO and Legacy product lines, consistent with the previous financial year. The primary focus during the period for the Medical segment is the continued commercialisation of SOZO.

For the half-year ended 31 December 2025, consistent with prior year, the Company reported all revenue associated with each contract as Revenue from Contracts with Customers, recognised over the term of each contract.

Notes to the consolidated financial statements

For the half-year ended 31 December 2025

SOZO

The SOZO business refers to the commercialisation efforts from the Company's core strategic focus areas. To date, this primarily includes revenue from SOZO contracts in the Oncology market.

Types of products

The principal products and services of the Medical segment are the development, manufacture and sale of BIS systems and software services with a focus on the early detection of lymphoedema, body composition analysis and for management of patients suffering from heart failure.

Major customers

The Group has several customers to which it provides both products and services. In the Medical segment, no customers accounted for more than 10% of the Group's revenues, consistent with the prior corresponding period. The Group does not believe there is inherent risk for future financial years that would stem from reliance on revenue growth from any one customer.

Segment revenue and gross margin

	Medical							
	Half-year ended 31 Dec 2025				Half-year ended 31 Dec 2024			
	SOZO \$000	Legacy \$000	Other \$000	Total \$000	SOZO \$000	Legacy \$000	Other \$000	Total \$000
Revenue								
Revenue from contracts with customers	7,225	236	-	7,461	5,738	238	-	5,976
Other revenue	-	-	55	55	-	-	32	32
Total revenue	7,225	236	55	7,516	5,738	238	32	6,008
Cost of goods								
Costs from contracts with customers	(622)	(60)	-	(682)	(493)	(60)	-	(553)
Other costs	(232)	(13)	(13)	(258)	(148)	(8)	(8)	(164)
Total cost of goods	(854)	(73)	(13)	(940)	(641)	(68)	(8)	(717)
Gross margin								
Gross margin – contracts with customers	6,603	176	-	6,779	5,245	178	-	5,423
Gross margin – other	(232)	(13)	42	(203)	(148)	(8)	24	(132)
Total gross margin	6,731	163	42	6,576	5,097	170	24	5,291
Gross margin %								
Contracts with customers	91%	75%	-	91%	91%	75%	-	91%
Total gross margin	88%	69%	76%	87%	89%	71%	75%	88%

Geographical segments

The following tables present revenue split by geographical segments for the half-year ended 31 December 2025. Revenue data is based on the location of the customer for geographical reporting purposes.

Australia is the corporate home office of the Group and the main domicile of its research and product development activities, intellectual property, corporate services (including executive personnel). The Australia/ROW geographical segment primarily sells Medical segment products to customers and distributors located in Australia, Europe, and the rest of the world, excluding the US.

Notes to the consolidated financial statements

For the half-year ended 31 December 2025

The Group's North American office in Carlsbad, California serves as the operational hub for finance and administration, selling, customer service, contract manufacturing and shipping Medical segment products to customers located in the US. Revenue from external customers by geographical location is detailed below:

Geographical segment revenue

Half-year ended 31 Dec 2025	Australia/ROW \$000	North America \$000	Total \$000
Revenue	789	6,672	7,461
Other revenue	29	26	55
Total revenue	818	6,698	7,516

Half-year ended 31 Dec 2024	Australia/ROW \$000	North America \$000	Total \$000
Revenue	490	5,486	5,976
Other revenue	20	12	32
Total revenue	510	5,498	6,008

All segment assets relating to the Group's operating segments as at 31 December 2025 are Medical.

6. Finance and other income and expenses

	Half-year ended 31 Dec 2025 \$000	Half-year ended 31 Dec 2024 \$000
Other income		
R&D tax incentive (i)	672	463
Other income	12	3
Total Other income	684	466

(1) The Group receives payments for research & development (R&D) tax credits under the AusIndustry R&D Tax Incentive program. The Group accrues for amounts when there is reasonable assurance of receipt. Whilst there is judgment involved in determining when there is reasonable assurance, the Group has a history of successful lodgings and receipts with the Australian Tax Office.

	Half-year ended 31 Dec 2025 \$000	Half-year ended 31 Dec 2024 \$000
Net finance (expense)/income		
Interest income - term deposits	460	480
Interest credit/(expense) - lease liability	8	(38)
Interest expense - borrowing costs	(1,872)	-
Total net finance (expense)/income	(1,404)	442

Notes to the consolidated financial statements

For the half-year ended 31 December 2025

7. Salaries and benefits

	Half-year ended 31 Dec 2025 \$000	Half-year ended 31 Dec 2024 \$000
Wages and salaries	8,191	7,671
Short-term incentives and sales commissions	749	610
Employee benefits	711	667
Superannuation	358	317
Taxes and other	623	570
Annual leave & long service leave	86	60
Capitalised employee costs	(386)	(435)
	10,332	9,460
Share-based payments	651	1,418
Total salaries and benefits	10,983	10,878

8. Cash and cash equivalents

	31 Dec 2025 \$000	30 Jun 2025 \$000
Cash at bank and in hand	1,141	504
Short-term deposits	17,706	21,679
Cash and cash equivalents	18,847	22,183

9. Trade and other receivables

	31 Dec 2025 \$000	30 Jun 2025 \$000
Trade receivables	2,323	1,926
Allowance for expected credit losses	(190)	(191)
R&D tax and other receivables	758	1,229
Total trade and other receivables	2,891	2,964

Fair value and credit risk

Due to the short-term nature of trade receivables, the carrying value is assumed to approximate its fair value. The maximum exposure to credit risk is the fair value of the receivables.

Trade receivables, which generally have 30 to 90 day payment terms, are recognised at fair value, less an expected credit loss (ECL) for impairment.

For trade receivables and contract assets, the Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit risk, instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix based on its historical credit loss experience, adjusted forward-looking factors specific to the debtors and the economic environment. Generally, the Group considers a debtor in default if debts are more than 90 days overdue and if there is evidence of financial difficulties of the debtor. In addition, the collectability of trade receivables is reviewed on an ongoing basis with individual debts that are known to be uncollectable written off when identified.

Notes to the consolidated financial statements

For the half-year ended 31 December 2025

The maximum exposure to credit risk at the reporting date is the higher of the carrying value or fair value of each class of receivables. No collateral is held as security.

When financial assets are recognised initially, they are measured at fair value. For assets not classified as fair value through profit or loss, they include directly attributable transaction costs.

10. Non-current Assets – Intangible assets and goodwill

Intangible assets

Intangible assets, including goodwill, totalled \$11.6 million at 31 December 2025 (30 June 2025: \$13.0 million).

During the half-year ended 31 December 2025 the Group generated intangible assets with a cost of \$0.5 million (31 December 2024: \$0.6 million). In accordance with AASB 138 Intangible Assets, the Group capitalises costs for product development projects. Initial capitalisation of costs is based on management's judgement that technological and economic feasibility is confirmed. In determining the amounts to be capitalised, management makes assumptions regarding the expected future cash generation of the project, discount rates to be applied and expected period of benefits.

Amortisation expense totalled \$1.9 million for the half-year ended 31 December 2025 (31 December 2024: \$1.9 million).

Other intangible assets decreased in the current period due to the amortisation of SOZO software, computer software and licenses. This decrease included changes arising from foreign currency exchange movements.

Goodwill

Goodwill totalled \$2.7 million at 31 December 2025 and \$2.8 million at 30 June 2025, with the movement relating to foreign exchange translation.

Goodwill is reviewed for impairment annually or more frequently if events or changes in circumstances indicate that the carrying value may be impaired.

At 31 December 2025, the Group found no evidence of indicators of impairment of goodwill or other assets, and as a result, no impairment test has been performed at the reporting date.

11. Issued capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. Fully paid ordinary shares carry one vote per share and carry the right to dividends.

Movements in ordinary share capital:

	Number of Ordinary Shares	\$000
At 31 December 2024	2,024,283,759	336,147
Issued under Non-executive Director and Employee Share Plans	3,202,411	-
At 30 June 2025	2,027,486,170	336,147
Issued under Non-executive Director and Employee Share Plans	10,813,353	-
At 31 December 2025	2,038,299,523	336,147

Notes to the consolidated financial statements

For the half-year ended 31 December 2025

12. Share-based payments

	Half-year ended 31 Dec 2025 \$000	Half-year ended 31 Dec 2024 \$000
Share-based payments to employees	619	1,338
Share-based payments to Non-Executive Directors	32	80
Total share-based payments	651	1,418

During the period, share-based payments issued to Executives under the Executive Share Plan (ESP) were \$82,000 (31 December 2024: \$62,000). Share-based payments to Non-Executive Directors totalled \$32,000 (31 December 2024: \$80,000).

During the period, 17,250,000 options (31 December 2024: 16,250,000) were granted under the Employee Incentive Plan (EIP). No options were granted to key management personnel ("KMP") in the current period.

During the period, no performance rights were granted under the EIP (31 December 2024: 23,126,097).

13. Borrowings

	31 Dec 2025 \$000	30 Jun 2025 \$000
Secured		
Other loans - Non-current	20,869	13,792
Total borrowings	20,869	13,792

Other loans relate to a five-year US\$15.0 million growth capital facility ('Facility') with SWK Funding LLC ('SWK'), a specialist finance company with a specific global healthcare sector focus. Borrowings are classified as non-current liabilities as the Group has a right to defer settlement for at least 12 months after the reporting date.

Interest

The Facility bears interest at SOFR (currently at 4.3%, with a floor at 4.25%) plus a margin of 9.5%. Interest payable at 31 December 2025 amounted to \$397,000 (30 June 2025: \$276,000).

Loan covenants

Under the terms of the SWK loan, which has a carrying amount of \$20.9 million at 31 December 2025, the Group is required to comply with the following financial covenants at the end of each quarter:

- Minimum consolidated unencumbered liquid assets to exceed US\$2.5 million.
- Total revenue to exceed prescribed quarterly minimums.

The Group has complied with the financial and non-financial covenants of its loan with SWK during the half-year ended 31 December 2025. The Group is actively working with the lender to address any risks relating to non-compliance with covenants.

Notes to the consolidated financial statements

For the half-year ended 31 December 2025

Warrants

Following the achievement of the prescribed FY25 sales target, in July 2025 the Group drew an additional US\$5.0 million under the Facility (Tranche 2). In conjunction with the drawdown of the Tranche 2 funding, the Group issued an additional 6,245,935 warrants and the interest-only period for the whole facility was extended by 12 months to February 2028.

Warrants issued in connection with the Facility are assessed to determine whether they meet the criteria for classification as equity or as financial liability. Warrants that meet the definition of an equity instrument are recognised in equity at their fair value on the grant date. When issued alongside a loan, the fair value of the warrants is recorded as a deduction from the loan's amortised cost and is amortised to profit or loss over the term of the loan using the effective interest method. Equity-classified warrants are not remeasured after initial recognition.

14. Related party disclosures

Ultimate parent and subsidiaries

ImpediMed Limited is the ultimate parent entity and the consolidated financial statements of the Group include the following subsidiaries:

Name	Principal activities	Country of incorporation	Equity interest	
			31 Dec 2025	30 Jun 2025
ImpediMed Incorporated	Manufacture and sale of BIS systems and software services	United States	100%	100%
ImpediMed Hellas	Development of BIS systems and software	Greece	100%	100%
ImpediMed TM Incorporated	Dormant	United States	100%	100%

For the half-year ended 31 December 2025 and for the corresponding prior period, other than the compensation payments (refer note 12), no transactions with Directors occurred that would be considered related party transactions.

Terms and conditions of transactions with related parties

Transactions with related parties are made on an arm's length basis at normal market prices and on normal commercial terms.

15. Commitments and contingencies

Expenditure commitments

At 31 December 2025, the Group has commitments of \$1.2 million (30 June 2025: \$5.6 million) relating to the funding of future product builds, clinical trials, advertising and promotion, and other activities. These expenditure commitments predominantly relate to SOZO products built to meet demand for SOZO devices.

Contingent liabilities

The Group had no contingent liabilities as at 31 December 2025.

16. Events occurring after the balance date

No matters or circumstances have arisen since 31 December 2025, other than those disclosed in the notes above that have significantly affected, or may significantly affect the interim consolidated financial report for the half-year ended 31 December 2025.

Notes to the consolidated financial statements

For the half-year ended 31 December 2025



**Shape the future
with confidence**

Ernst & Young
111 Eagle Street
Brisbane QLD 4000 Australia
GPO Box 7878 Brisbane QLD 4001

Tel: +61 7 3011 3333
Fax: +61 7 3011 3100
ey.com/au

Independent auditor's review report to the members of ImpediMed Limited

Conclusion

We have reviewed the accompanying condensed half-year financial report of ImpediMed Limited (the Company) and its subsidiaries (collectively the Group), which comprises the consolidated statement of financial position as at 31 December 2025, the consolidated statement of profit and loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, explanatory notes and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of the Group does not comply with the *Corporations Act 2001*, including:

- a. Giving a true and fair view of the consolidated financial position of the Group as at 31 December 2025 and of its consolidated financial performance for the half-year ended on that date; and
- b. Complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity* (ASRE 2410). Our responsibilities are further described in the *Auditor's responsibilities for the review of the half-year financial report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our review of the half-year financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Material uncertainty related to going concern

We draw attention to Note 1 Basis of Preparation – Going Concern in the half-year financial report, which describes the principal conditions about the Group's ability to continue as a going concern. These events or conditions indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

Directors' responsibilities for the half-year financial report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibilities for the review of the half-year financial report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2025 and its

A member firm of Ernst & Young Global Limited
Liability limited by a scheme approved under Professional Standards Legislation

Notes to the consolidated financial statements

For the half-year ended 31 December 2025



**Shape the future
with confidence**

performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

A handwritten signature in black ink that reads 'Ernst & Young' with a stylized flourish underneath.

Ernst & Young

A handwritten signature in black ink that reads 'm nair' with a stylized flourish underneath.

Madhu Nair
Partner
Brisbane
26 February 2026

A member firm of Ernst & Young Global Limited
Liability limited by a scheme approved under Professional Standards Legislation

For personal use only